LON:VECVectura Group Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vectura Group PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 98.70 +0.90 (+0.92 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range 93.78Now: GBX 98.70▼ 100.4250-Day Range 86.90MA: GBX 96.13▼ 105.2052-Week Range 59.10Now: GBX 98.70▼ 107Volume533,429 shsAverage Volume4.61 million shsMarket Capitalization£594.20 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendInsider TradesHeadlinesOptions Chain Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD. Its generic partnering products include flutiform, VR315, VR506, VR730, VR632, VR2081, VR410, and Ellipta for the treatment of asthma; and Phase I clinical stage product is the VR475 (US) for the treatment of severe adult asthma. The company's Phase II clinical stage products comprise VR465 for treating respiratory syncytial virus infection; VR647 for the treatment of paediatric asthma; and VR736 for the treatment severe influenza. Its Phase III clinical stage products include QVM149 for the treatment of asthma; and VR475 (EU) for the treatment of severe adult asthma. The company also provides dry powder inhalers; pressurized meter dose inhalers; and smart nebulizers. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingVectura Group has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 114.50, Vectura Group has a potential upside of 16.0% from its current price of GBX 98.70.Amount of Analyst CoverageVectura Group has only been the subject of 2 research reports in the past 90 days. Previous Next 3.6 Community Rank Outperform VotesVectura Group has received 839 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVectura Group has received 325 “underperform” votes. (Add your “underperform” vote.)Community SentimentVectura Group has received 72.08% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Vectura Group and other stocks. Vote “Outperform” if you believe VEC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VEC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVectura Group does not currently pay a dividend.Dividend GrowthVectura Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vectura Group insiders have sold 747.41% more of their company's stock than they have bought. Specifically, they have bought £11,040 in company stock and sold £93,554.56 in company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vectura Group are expected to decrease by -100.00% in the coming year, from GBX 1,036.31 to GBX 0 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vectura Group is -29.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vectura Group is -29.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVectura Group has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.20 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical Current SymbolLON:VEC Previous Symbol CUSIPN/A CIKN/A Webwww.vectura.com Phone+44-1249-667700Debt Debt-to-Equity Ratio1.81 Current Ratio2.28 Quick Ratio1.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio0.10 P/E GrowthN/A Sales & Book Value Annual Sales£178.30 million Price / Sales3.33 Cash FlowGBX 12.02 per share Price / Cash Flow8.21 Book ValueGBX 69.20 per share Price / Book1.43Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees478 Outstanding Shares602,022,976Market Cap£594.20 million Next Earnings DateN/A OptionableOptionable LSE:VEC Rates by TradingView Receive VEC News and Ratings via Email Sign-up to receive the latest news and ratings for VEC and its competitors with MarketBeat's FREE daily newsletter. Vectura Group (LON:VEC) Frequently Asked Questions How has Vectura Group's stock been impacted by COVID-19 (Coronavirus)? Vectura Group's stock was trading at GBX 81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VEC shares have increased by 21.9% and is now trading at GBX 98.70. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Vectura Group? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vectura Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vectura Group. How often does Vectura Group pay dividends? What is the dividend yield for Vectura Group? Vectura Group announced a dividend on Tuesday, September 10th. Stockholders of record on Monday, October 14th will be given a dividend of GBX 6 per share on Friday, October 25th. The ex-dividend date is Monday, October 14th. The official announcement can be viewed at this link. View Vectura Group's dividend history. What price target have analysts set for VEC? 4 brokers have issued 1-year price objectives for Vectura Group's shares. Their forecasts range from GBX 114 to GBX 115. On average, they anticipate Vectura Group's stock price to reach GBX 114.50 in the next year. This suggests a possible upside of 16.0% from the stock's current price. View analysts' price targets for Vectura Group. Has Vectura Group been receiving favorable news coverage? Media headlines about VEC stock have trended somewhat negative on Tuesday, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vectura Group earned a news impact score of -1.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Vectura Group. Who are some of Vectura Group's key competitors? Some companies that are related to Vectura Group include Opthea (OPT), Mayne Pharma Group (MYX), Medical Developments International (MVP), Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Allergy Therapeutics (AGY), NanoViricides (NNVC), Trilogy International Partners (TRL), Recce Pharmaceuticals (RCE), Futura Medical (FUM), Vita Life Sciences (VLS), Pharmaxis (PXS), Antisense Therapeutics (ANP), China Pharma (CPHI) and Avivagen (VIV). View all competitors. What other stocks do shareholders of Vectura Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vectura Group investors own include Hikma Pharmaceuticals (HIK), SkyePharma (SKP), BTG (BTG), iRobot (IRBT), SINR PHAR/PAR VTG FPD 0.01 (SPH), Sirius Minerals (SXX), Coats Group (COA), Griffin Mining (GFM), HSBC (HSBA) and Inmarsat (ISAT). Who are Vectura Group's key executives? Vectura Group's management team includes the following people: Mr. James Ward-Lilley, CEO & Exec. Director (Age 54)Mr. Paul Fry, CFO & Exec. DirectorMr. Anthony Fitzpatrick, Exec. VP of OperationsElizabeth Knowles, Director of Investor Relations & AnalysisMr. John Murphy, Gen. Counsel & Company Sec. (Age 66) What is Vectura Group's stock symbol? Vectura Group trades on the London Stock Exchange (LON) under the ticker symbol "VEC." How do I buy shares of Vectura Group? Shares of VEC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Vectura Group's stock price today? One share of VEC stock can currently be purchased for approximately GBX 98.70. How big of a company is Vectura Group? Vectura Group has a market capitalization of £594.20 million and generates £178.30 million in revenue each year. Vectura Group employs 478 workers across the globe. What is Vectura Group's official website? The official website for Vectura Group is www.vectura.com. How can I contact Vectura Group? Vectura Group's mailing address is One Prospect West, CHIPPENHAM, SN14 6FH, United Kingdom. The company can be reached via phone at +44-1249-667700. This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
